Form 4: PACB Grants Equity to Chief Accounting Officer

Pacific Biosciences of California granted 89,835 Restricted Stock Units and 179,670 stock options to its Chief Accounting Officer, Michele Farmer.

Summary

• Michele Farmer, Chief Accounting Officer of Pacific Biosciences of California, Inc. (PACB), was granted 89,835 Restricted Stock Units (RSUs) and 179,670 stock options on February 27, 2026.
• The RSUs will vest in three equal annual installments on February 15 of 2027, 2028, and 2029, contingent on continued service.
• The stock options have an exercise price of $1.68 per share and will vest in 36 equal monthly installments beginning on March 27, 2026, also subject to continued service.
• Following these transactions, Michele Farmer beneficially owns 308,927 shares of common stock (including RSUs) and 179,670 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It represents a routine executive compensation action that aligns management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The equity grants align the Chief Accounting Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The grants are a standard component of executive compensation packages, reflecting ongoing commitment to key management personnel.

Risks

• The value of the granted equity compensation is subject to the future performance of PACB's stock price, which can be volatile.
• Potential dilution for existing shareholders if all options are exercised and RSUs vest, although this is a standard aspect of equity compensation plans.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's equity compensation.

Industry Context

StockSavvy.ai notes that equity compensation, including Restricted Stock Units and stock options, is a prevalent practice in the biotechnology and genomics industry. It serves as a critical tool for attracting, retaining, and motivating key executives and employees in a highly competitive talent market, aligning their long-term incentives with company growth and shareholder value creation.

Comparison to Industry Standards

• The structure of these equity grants, involving both RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotech and technology sectors.
• The use of performance-based or time-based vesting is standard, aiming to ensure executive retention and incentivize sustained performance, similar to practices at companies like Illumina or Thermo Fisher Scientific.

Related Party Transactions

• The equity grants to Michele Farmer, Chief Accounting Officer, constitute a related party transaction as they involve compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon vesting and exercise, but also benefit from increased management alignment and retention.
• Employees (Michele Farmer): Direct financial benefit through equity compensation, incentivizing continued service and performance.

Next Steps

• Monthly vesting of 179,670 stock options over 36 months, commencing March 27, 2026.
• Annual vesting of 89,835 Restricted Stock Units in three equal installments on February 15, 2027, 2028, and 2029.

Key Dates

Keywords

PACB, Pacific Biosciences, Michele Farmer, Chief Accounting Officer, Form 4, SEC filing, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Insider Transaction, Executive Compensation